Tag: Parkinson’s
AAN: Tavapadon as Adjunct to Levodopa Ups Daily ON Time in Parkinson Disease
Significant reduction also seen in change from baseline in daily OFF times versus placebo
Globally, 25.2 Million Projected to Be Living With Parkinson Disease in 2050
Primary contributor to increase in cases from 2021 to 2050 is population aging, followed by population growth
AAN: Obstructive Sleep Apnea Linked to Increased Incidence of Parkinson Disease
Incidence of Parkinson disease significantly lower with early CPAP treatment, but no reduction seen with late CPAP treatment
Study Finds Exenatide Not Beneficial for Parkinson Disease
No evidence seen to support GLP-1 receptor agonist exenatide as disease-modifying treatment for Parkinson disease
FDA Approves Wearable Infusion Device for Advanced Parkinson Disease
Onapgo is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in patients with advanced disease
Hearing Impairment Tied to Higher Risk for New Parkinson Disease Diagnosis
In a recent study, risk increased 57 percent for every 10-dB increase in speech-reception threshold
Multiple Penicillin Courses Linked to Modestly Lower Risk for Parkinson Disease
Increase in PD risk seen in association with exposure to two or more courses of antifungals one to five years prior
FDA Approves Vyalev for Advanced Parkinson Disease
Vyalev is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for treatment of motor fluctuations
Air Pollution Exposure Increases Risk for Parkinson Disease
Among those with Parkinson disease, air pollution tied to higher risk for developing akinetic rigid disease and dyskinesia
SGLT2i Use Linked to Lower Risk for Neurodegenerative Disease in T2DM
Reduced risk for Alzheimer disease, vascular dementia, and Parkinson disease seen with SGLT2i use in type 2 diabetes
